MeSH tree: E05.478.550.520
A discovery made 50 years ago helped establish the field of human retrovirology, advance understanding of the human immune system and contribute to a revolution in cancer treatment. A new perspective in Science examines that ...
Sep 14, 2026
0
4
CAR T-cell therapy has transformed cancer care, offering new hope to patients with aggressive blood cancers who once had few treatment options. But for some patients, the powerful immunotherapy can trigger a potentially life-threatening ...
Aug 19, 2026
0
7
For more than a decade, CAR-T cell therapy has been one of the biggest breakthroughs in cancer medicine. By reprogramming a patient's own immune cells to attack cancer, doctors have produced remarkable results against certain ...
Aug 16, 2026
0
29
For patients with blood cancers like leukemia and lymphoma, the immunotherapy known as CAR-T cell therapy can be lifesaving. Doctors remove a patient's immune cells, called T cells, engineer them in the lab to better recognize ...
Aug 12, 2026
0
66
Researchers at the USC Viterbi School of Engineering and Keck School of Medicine of USC have engineered a genetic tool that addresses one of the most persistent obstacles in cancer immunotherapy: the physical softness of ...
Aug 12, 2026
0
7
Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. But in some patients, ...
Jul 24, 2026
0
7
In a phase 1 clinical trial, treatment with the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma, many of whom had already undergone multiple other cancer treatments, ...
Jul 22, 2026
0
9
A leading-edge immunotherapy may extend survival for patients with one of the most aggressive forms of blood cancer, according to newly published five-year results from a major clinical trial in the Blood Journal. The clinical ...
Jul 14, 2026
0
6
Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival ...
Jul 7, 2026
0
7
Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized. By combining genetic and proteomic analyses, the scientists ...
Jul 3, 2026
0
7
